Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676555 · ClinicalTrials.gov registry record
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
A clinical trial of Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2
- Enrollment target
- 2
- Study locations
NCT04676555: Completed study of Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT04676555 is a study of Relapsing Forms of Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04676555, a study of Relapsing Forms of Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
Primary Outcome
Describe and compare the time spent by Healthcare Providers (in minutes) in the treatment preparation, administration and post-treatment observation of Ocrelizumab and Ofatumumab in patients with Relapsing forms of Multiple Sclerosis at each event (initial, loading and subsequent doses).
Conditions Studied
Interventions
- DRUG Ocrelizumab
- DRUG Ofatumumab
Study Locations (2)
Maryland
- Novartis Investigative Site - Lutherville
Victoria
- Novartis Investigative Site - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2021-10-21 |
What the finished NCT04676555 record still lists
NCT04676555 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 1 condition, with Relapsing Forms of Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab is the first listed.
NCT04676555 reports a single indexed study location in Maryland, Victoria.
Frequently Asked Questions
What is clinical trial NCT04676555 about?
NCT04676555 is a clinical study titled "Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis". This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
What is the current status of trial NCT04676555?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2021-05-11. Estimated completion is 2021-10-21.
What conditions does trial NCT04676555 study?
This clinical trial studies the following conditions: Relapsing Forms of Multiple Sclerosis.
What interventions are being tested in trial NCT04676555?
The interventions under investigation include: Ocrelizumab (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT04676555?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04676555 being conducted?
This trial has 2 study locations across Maryland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Forms of Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI